fda glp-1 compounding crackdown news october 2025 Despite crackdown, unapproved GLP-1s still threaten the industry Non-Traditional Channels: The Compounded GLP-1

Additional research on anti-inflammatory, antibacterial, and other aspects is crucial to support its clinical use

Stephenson currently serves on the Plaintiffs Executive Committee in In re: GLP-1 Receptor Agonists Products Liability Litigation (MDL 3094) and has been actively involved in other major MDLs, including Johnson & Johnson Talcum Powder Litigation (MDL 2738) and Proton Pump Inhibitor Litigation (MDL 2789)

As a point of reference, the International Peptide Society notes that epithalon administered intranasally would require two to three times the injectable dosage to achieve comparable bioavailability, and thus effect

Domico, L

That company was once licensed to operate a compounding pharmacy in south-west Sydney